Christus St. Frances Cabrini Health System Offers COVID-19 At Risk Patients REGN-COV2 via Compassionate Use

Nov 16, 2020 | COVID-19, Monoclonal Antibodies, News, Regeneron, REGN-COV2

Christus St. Frances Cabrini Health System Offers COVID-19 At Risk Patients REGN-COV2 via Compassionate Use

CHRISTUS St. Frances Cabrini Health System (Christus Cabrini) is one of the first health centers in Louisiana to offer the investigational monoclonal antibody developed by Regeneron known as REGN-COV2 to treat mild-to-moderate SARS-CoV-2 (COVID-19). This particular investigational product is now available via compassionate use (see protocol). Regeneron has submitted an application for an emergency use authorization. The Eli Lilly monoclonal antibody product known as LY-COV555 (Bamlanivimab) has been approved by the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA).

The POTUS Treatment

Many regional health systems and trial site organizations have emphasized that the same monoclonal antibody that POTUS used during his time at the hospital is now stocked and ready for patient administration. Now available under compassionate use, CHRISTUS St. Frances Cabrini Health System recently touted its’ CHRISTUS Community Clinic has stocked REGN-COV2 and will commence administering treatment today for COVID-19 positive patients who face greater risk for hospitalization. America now faces a second wave or spike in coronavirus cases so the timing is good.

Current Supply & Inclusion Criteria for REGN-COV2

CHRISTUS Cabrini reports that the current supply is reserved for patients who face increased risk for severe illness. Patients must meet at least three of the following underlying medical conditions to qualify for the treatment: Coronary Artery Disease, Atrial Fibrillation, Congestive Heart Failure, Hypertension, Diabetes Mellitus Type 1 or 2, Acute Kidney Injury, Kidney Disease Stages 3-5, end-stage Renal Disease, or Morbid Obesity with a BMI >40.

Key Executive Point of View

“This treatment can be life-saving to those who are most vulnerable to severe illness. Used as one of the treatments given to President Trump, he credited it for his speedy recovery from COVID-19. I am elated CHRISTUS St. Frances Cabrini will serve the community in this capacity by providing this treatment,” said Jose M. Zapatero, M.D., Chief Medical Officer and Vice President of Medical Affairs, CHRISTUS St. Frances Cabrini Health System.

Outside of CHRISTUS St. Frances Cabrini Health System

Those patients undergoing treatment outside of the health system for COVID-19 can still access this powerful investigational product via a process established by CHRISTUS:  providers can order the antibody test to be done at the Cabrini Outpatient lab. If the test is negative, the patient’s history and test results should then be sent to CHRISTUS Community Clinic. 

Treatment Timing

The actual investigational product must be administered within 24 hours of obtaining the antibody test. It requires an intravenous infusion and monitoring after the procedure. Patients should expect the process to take up to eight hours.  CHRISTUS reports that modifications are expected to treatment criteria as information continues to evolve.

Emergency Authorized Use (EUA)

Although the recent press release issued by CHRISTUS mentions that the emergency use authorization of monoclonal antibodies was recently authorized by the FDA to treat mild-to-moderate cases of COVID-19 infection, this action was for Eli Lilly’s LYCoV-555 reported on Nov. 9. Regeneron’s REGN-COV2 is still under a compassionate use access or clinical trial.

Regeneron submitted an application for EUA on Oct. 7

About CHRISTUS St. Frances Cabrini Health System

A part of CHRISTUS Health, CHRISTUS Health St. Frances Cabrini System, located in Alexandria Louisiana, is a 241-bed facility that employs about 1,600 associates and a medical staff of over 325 physician. Accredited by the Joint Commission, CHRISTUS Cabrini offers comprehensive inpatient and outpatient services.

Christus Community Clinic is located at 3000 South MacArthur Drive. For more information on CHRISTUS Cabrini COVID-19 response, visit their website

Lead Research/Investigator

Jose M. Zapatero, MD, Chief Medical Officer and Vice President of Medical Affairs

Call to Action:  For residents that have been diagnosed with COVID-19 and face additional risks for hospitalization, CHRISTUS Community Clinic offers the same powerful investigational product offered to POTUS.


Pin It on Pinterest